{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443834989
| IUPAC_name = (8''R'',9''S'',10''R'',13''S'',14''S'',17''R'')-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14-decahydrocyclopenta[''a'']phenanthren-3-one
| image = Gestodene.svg
| image2 = Gestodeno3D.png

<!--Clinical data-->
| tradename = Femodene, Femodette, Gynera, Harmonet, Meliane, Minesse, Minulet, others
| Drugs.com = {{drugs.com|international|gestodene}}
| pregnancy_category = X
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 87–99%<ref name="pmid12215716">{{cite journal | vauthors = Stanczyk FZ | title = Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception | journal = Rev Endocr Metab Disord | volume = 3 | issue = 3 | pages = 211–24 | year = 2002 | pmid = 12215716 | doi = 10.1023/A:1020072325818| url = }}</ref>
| elimination_half-life = 12–14 hours<ref name="pmid12215716" />
| excretion = [[Urine]]

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 60282-87-3
| ATC_prefix = G03
| ATC_suffix = AA10
| ATC_supplemental = {{ATC|G03|AB06}} (only combinations with [[estrogen]]s)
| PubChem = 3033968
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06730
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2298532
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1664P6E6MI
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D04316
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1213583

<!--Chemical data-->
| C=21 | H=26 | O=2 
| molecular_weight = 310.430 g/mol
| SMILES = O=C4\C=C3/[C@@H]([C@H]2CC[C@]1([C@@H](/C=C\[C@]1(C#C)O)[C@@H]2CC3)CC)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H26O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,10,12-13,16-19,23H,3,5-9,11H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = SIGSPDASOTUPFS-XUDSTZEESA-N
| synonyms = <small>SHB-331; δ<sup>15</sup>-Norgestrel; 15-Dehydronorgestrel; 17α-Ethynyl-18-methyl-19-nor-δ<sup>15</sup>-testosterone; 17α-Ethynyl-18-methylestra-4,15-dien-17β-ol-3-one; 13β-Ethyl-18,19-dinor-17α-pregna-4,15-dien-20-yn-17β-ol-3-one</small>
|drug_name=|alt=|caption=|type=|MedlinePlus=|licence_EU=|pregnancy_AU=|pregnancy_US=|licence_US=|ChEBI=135323|ChEBI_Ref={{ebicite|correct|EBI}}}}

'''Gestodene''', sold under the brand names '''Femodene''', '''Femodette''', '''Gynera''', '''Harmonet''', '''Meliane''', '''Minesse''', and '''Minulet''' among others, is a [[progestin]] which is used in combination with the [[estrogen]] [[ethinylestradiol]] as a [[hormonal contraceptive]].<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA595|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=595–}}</ref><ref name="MortonHall1999">{{cite book|author1=I.K. Morton|author2=Judith M. Hall|title=Concise Dictionary of Pharmacological Agents: Properties and Synonyms|url=https://books.google.com/books?id=mqaOMOtk61IC&pg=PA132|date=31 October 1999|publisher=Springer Science & Business Media|isbn=978-0-7514-0499-9|pages=132–}}</ref> It is marketed in [[Europe]] but is not available in the [[United States]].<ref name="Becker2001">{{cite book|author=Kenneth L. Becker|title=Principles and Practice of Endocrinology and Metabolism|url=https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1024|year=2001|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-1750-2|pages=1024–}}</ref><ref name="JiangHe2016">{{cite book|author1=Qi Jiang|author2=Weili He|title=Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments|url=https://books.google.com/books?id=NxZjDAAAQBAJ&pg=PA135|date=25 May 2016|publisher=CRC Press|isbn=978-1-4822-5937-7|pages=135–}}</ref>

==Medical uses==

===Contraception===
Gestodene is neutral in terms of [[androgen]]ic activity, meaning that contraceptive pills containing gestodene do not exhibit the androgenic [[side effect]]s (e.g., [[acne]], [[hirsutism]]) sometimes associated with second-generation contraceptive pills such as those containing [[levonorgestrel]].<ref>http://dermnetnz.org/treatments/antiandrogens.html</ref>

The estrogen dosage in third-generation contraceptive pills (including those containing gestodene) is lower than that in second-generation oral contraceptives, reducing the likelihood of [[weight gain]], [[breast tenderness]], and [[migraine]].<ref>{{ cite journal | author = Festin | title = Progestogens in combined oral contraceptives for contraception | journal = The WHO Reproductive Health Library | year = 2006 }}</ref>

Third-generation oral contraceptives are also suitable for use in patients with [[diabetes]] or [[lipid disorder]]s because they have minimal impact on [[blood glucose]] levels and the [[lipid profile]].<ref>{{ cite journal | author = Cerel-Suhl | title = Update on Oral Contraceptive Pills | journal = American Family Physician | volume = 60 | issue = 7 | pages = 2073–2084 | year = 1999 }}</ref>

===Available forms===
Products containing gestodene include:

*'''Melodene-15''', '''Mirelle''', and '''Minesse''' which contain 15&nbsp;μg of ethinylestradiol and 60&nbsp;μg of gestodene;
*'''Meliane''', '''Sunya''', '''Femodette''', and '''Millinette 20/75''' which contain 20&nbsp;μg of ethinylestradiol and 75&nbsp;μg of gestodene; and
*'''Gynera''', '''Minulet''', '''Femoden''', '''Femodene''', '''Katya''' and '''Millinette 30/75''' which contain 30&nbsp;μg of ethinylestradiol and 75&nbsp;μg of gestodene.<ref>{{cite web |url=http://www.bayerscheringpharma.es/ebbsc/cms/es/_galleries/download/s_mujer/prospectos/MelodeneS.pdf |title=Archived copy |accessdate=2011-04-20 |deadurl=yes |archiveurl=https://web.archive.org/web/20110722130555/http://www.bayerscheringpharma.es/ebbsc/cms/es/_galleries/download/s_mujer/prospectos/MelodeneS.pdf |archivedate=2011-07-22 |df= }}</ref>

==Side effects==
Women who take oral contraceptives containing gestodene are 5.6 times as likely to develop [[venous thromboembolism]] than women who do not take any contraceptive pill, and 1.6 times as likely to develop venous thromboembolism compared to women taking oral contraceptives containing [[levonorgestrel]].<ref>{{cite journal | author = Lidegaard| title = Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses | journal = BMJ | volume = 343 | pages = 1–15 | year = 2011 | doi= 10.1136/bmj.d6423 | pmid=22027398 | pmc=3202015|display-authors=etal}}</ref>

==Pharmacology==
Gestodene is a potent [[progestogen]], and also possesses weak [[androgen]]ic, [[antimineralocorticoid]], and [[glucocorticoid]] activity.<ref name="FuhrmannSlater1995">{{cite journal|last1=Fuhrmann|first1=Ulrike|last2=Slater|first2=Emily P.|last3=Fritzemeier|first3=Karl-Heinrich|title=Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays|journal=Contraception|volume=51|issue=1|year=1995|pages=45–52|issn=0010-7824|doi=10.1016/0010-7824(94)00003-F}}</ref><ref name="SchindlerCampagnoli2003">{{cite journal|last1=Schindler|first1=Adolf E|last2=Campagnoli|first2=Carlo|last3=Druckmann|first3=René|last4=Huber|first4=Johannes|last5=Pasqualini|first5=Jorge R|last6=Schweppe|first6=Karl W|last7=Thijssen|first7=Jos H.H|title=Classification and pharmacology of progestins|journal=Maturitas|volume=46|year=2003|pages=7–16|issn=0378-5122|doi=10.1016/j.maturitas.2003.09.014|pmid=14670641}}</ref> It has relatively high [[affinity (pharmacology)|affinity]] for the [[androgen receptor]] (AR), with twice that of [[levonorgestrel]] (which is known to be one of the more androgenic [[19-nortestosterone]] derivatives).<ref name="pmid24485094">{{cite journal | vauthors = Stanczyk FZ, Archer DF | title = Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations | journal = Contraception | volume = 89 | issue = 4 | pages = 242–52 | year = 2014 | pmid = 24485094 | doi = 10.1016/j.contraception.2013.12.003 | url = }}</ref> However, the ratio of progestogenic to androgenic effects of gestodene is distinctly higher than that of levonorgestrel, and the increase in [[sex hormone-binding globulin]] (SHBG) levels (a marker of androgenicity) produced by oral contraceptives containing gestodene is slightly less than that produced by oral contraceptives containing desogestrel (which is known to be one of the more weakly androgenic 19-nortestosterone derivatives).<ref name="pmid24485094" /> In addition, no difference in [[acne]] incidence has been observed with oral contraceptives containing gestodene and oral contraceptives containing desogestrel.<ref>{{cite journal|last1=Arowojolu|first1=AO|last2=Gallo|first2=MF|last3=Lopez|first3=LM|last4=Grimes|first4=DA|title=Combined oral contraceptive pills for treatment of acne.|journal=The Cochrane database of systematic reviews|date=11 July 2012|issue=7|pages=CD004425|pmid=22786490}}</ref> Moreover, gestodene has been found to strongly [[enzyme inhibitor|inhibit]] [[5α-reductase]] ''[[in vitro]]'' (14.5% and 45.9% inhibition at 0.1&nbsp;μM and 1&nbsp;μM, respectively),<ref name="pmid16112947">{{cite journal | vauthors = Kuhl H | title = Pharmacology of estrogens and progestogens: influence of different routes of administration | journal = Climacteric | volume = 8 Suppl 1 | issue = | pages = 3–63 | year = 2005 | pmid = 16112947 | doi = 10.1080/13697130500148875 | url = }}</ref> and this action was substantially greater than that of desogestrel or levonorgestrel.<ref name="pmid24485094" /> Taken together, like desogestrel, gestodene appears to have a low potential for androgenic effects.<ref name="pmid24485094" /> In addition to the AR, gestodene has very high [[affinity (pharmacology)|affinity]] for the [[mineralocorticoid receptor]] (MR), but only a relatively weak antimineralocorticoid effect that is comparable to that of [[progesterone]].<ref name="pmid24485094" /> Gestodene binds to SHBG with relatively high [[affinity (pharmacology)|affinity]], and is 75% bound to the protein in circulation.<ref name="SchindlerCampagnoli2003" /><ref name="pmid24485094" />

Although gestodene does not bind to the [[estrogen receptor]] itself, the drug may have some [[estrogen]]ic activity, and this would appear to be mediated by its weakly estrogenic metabolites 3β,5α-tetrahydrogestodene and to a lesser extent 3α,5α-tetrahydrogestodene.<ref name="pmid10828854">{{cite journal | vauthors = Lemus AE, Zaga V, Santillán R, García GA, Grillasca I, Damián-Matsumura P, Jackson KJ, Cooney AJ, Larrea F, Pérez-Palacios G | title = The oestrogenic effects of gestodene, a potent contraceptive progestin, are mediated by its A-ring reduced metabolites | journal = J. Endocrinol. | volume = 165 | issue = 3 | pages = 693–702 | year = 2000 | pmid = 10828854 | doi = 10.1677/joe.0.1650693| url = }}</ref>

Based on the dosage necessary to inhibit [[ovulation]] in women, gestodene is the most potent of all of the currently used contraceptive progestogens.<ref name="Skouby1997">{{cite book|author=Sven O. Skouby|title=Clinical Perspectives on a New Gestodene Oral Contraceptive Containing 20μg of Ethinylestradiol|url=https://books.google.com/books?id=IYj54F5zvM4C&pg=PA19|date=15 July 1997|publisher=CRC Press|isbn=978-1-85070-786-8|pages=19–}}</ref><ref name="pmid15697108">{{cite journal | vauthors = Benagiano G, Primiero FM, Farris M | title = Clinical profile of contraceptive progestins | journal = Eur J Contracept Reprod Health Care | volume = 9 | issue = 3 | pages = 182–93 | year = 2004 | pmid = 15697108 | doi = 10.1080/13625180400007736| url = }}</ref><ref name="ShoupeHaseltine2012">{{cite book|author1=Donna Shoupe|author2=Florence P. Haseltine|title=Contraception|url=https://books.google.com/books?id=cpDhBwAAQBAJ&pg=PA62|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-1-4612-2730-4|pages=62–}}</ref> The oral dosage of gestodene required for ovulation inhibition is 30 or 40&nbsp;μg per day.<ref name="pmid15697108" /><ref name="pmid19434889">{{cite journal | vauthors = Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH | title = Classification and pharmacology of progestins | journal = Maturitas | volume = 61 | issue = 1-2 | pages = 171–80 | year = 2008 | pmid = 19434889 | doi = 10.1016/j.maturitas.2008.11.013| url = }}</ref> This is about 10,000 times lower than the oral dosage of progesterone required to inhibit ovulation (300&nbsp;mg/day).<ref name="SchindlerCampagnoli2003" /><ref name="Kuhl2011">{{cite journal | author = Kuhl H | title = Pharmacology of Progestogens | journal = J Reproduktionsmed Endokrinol | year = 2011 | volume = 8 | issue = 1 | pages = 157–177 | format = PDF | url = http://www.kup.at/kup/pdf/10168.pdf}}</ref> A dosage of gestodene of 75&nbsp;μg/day is used in contraceptives.<ref name="ShoupeHaseltine2012" />

==Chemistry==
{{See also|List of steroidal progestogens}}

Gestodene, also known as '''17α-ethynyl-18-methyl-19-nor-δ<sup>15</sup>-testosterone''', as well as '''17α-ethynyl-18-methylestra-4,15-dien-17β-ol-3-one''' or '''13β-ethyl-18,19-dinor-17α-pregna-4,15-dien-20-yn-17β-ol-3-one''', is a [[synthetic compound|synthetic]] [[estrane]] [[steroid]] and a [[chemical derivative|derivative]] of [[testosterone]].<ref name="Elks2014" /><ref name="Drugs.com">https://www.drugs.com/international/gestodene.html</ref> It is more specifically a derivative of [[norethisterone]] (17α-ethynyl-19-nortestosterone) and is a member of the [[gonane]] (18-methylestrane) subgroup of the [[19-nortestosterone]] family of progestins.<ref name="StraussBarbieri2009">{{cite book|author1=Jerome Frank Strauss|author2=Robert L. Barbieri|title=Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management|url=https://books.google.com/books?id=NudwnhxY8kYC&pg=PA878|year=2009|publisher=Elsevier Health Sciences|isbn=1-4160-4907-X|pages=878–}}</ref> Gestodene is almost identical to [[levonorgestrel]] in terms of [[chemical structure]], differing only in having an additional [[double bond]] between the C15 and C16 positions, and for this reason is also known as '''δ<sup>15</sup>-norgestrel''' or as '''15-dehydronorgestrel'''.<ref name="pmid8946122">{{cite journal | vauthors = Ellen JM, Irwin CE | title = Primary care management of adolescent sexual behavior | journal = Curr. Opin. Pediatr. | volume = 8 | issue = 5 | pages = 442–8 | year = 1996 | pmid = 8946122 | doi = | url = }}</ref><ref name="FritzSperoff2011">{{cite book|author1=Marc A. Fritz|author2=Leon Speroff|title=Clinical Gynecologic Endocrinology and Infertility|url=https://books.google.com/books?id=Ll73ZsBKLkwC&pg=PA966|year=2011|publisher=Lippincott Williams & Wilkins|isbn=978-0-7817-7968-5|pages=966–}}</ref>

==History==
Gestodene was introduced in 1987.<ref name="RunnebaumRabe2012">{{cite book|author1=Benno Clemens Runnebaum|author2=Thomas Rabe|author3=Ludwig Kiesel|title=Female Contraception: Update and Trends|url=https://books.google.com/books?id=LtT6CAAAQBAJ&pg=PA13|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-73790-9|pages=13–}}</ref>

==Society and culture==

===Generic name===
''Gestodene'' is the [[generic term|generic name]] of the drug and its {{abbrlink|INN|International Nonproprietary Name}}, {{abbrlink|USAN|United States Adopted Name}}, {{abbrlink|BAN|British Approved Name}}, and {{abbrlink|DCF|Dénomination Commune Française}}.<ref name="Elks2014" /><ref name="MortonHall1999" />

===Brand names===
Gestodene is marketed as a contraceptive in combination with ethinylestradiol under a variety of brand names including Femoden, Femodene, Femodette, Gynera, Harmonet, Lindynette, Logest, Meliane, Millinette, Minesse, Minulet, Mirelle, and Triadene as well as many others.<ref name="Drugs.com" />

==Footnotes==
{{Reflist|2}}

{{Progestogens and antiprogestogens}}
{{Androgens and antiandrogens}}
{{Mineralocorticoids and antimineralocorticoids}}
{{Progesterone receptor modulators}}
{{Androgen receptor modulators}}
{{Glucocorticoid receptor modulators}}
{{Mineralocorticoid receptor modulators}}

[[Category:5α-Reductase inhibitors]]
[[Category:Alcohols]]
[[Category:Alkynes]]
[[Category:Androgens and anabolic steroids]]
[[Category:Antimineralocorticoids]]
[[Category:Estranes]]
[[Category:Glucocorticoids]]
[[Category:Ketones]]
[[Category:Progestogens]]